摘要
目的:探讨淋巴瘤化疗后侵袭性肺部真菌感染(PFI)的临床特征。方法:收集淋巴瘤化疗后合并侵袭性肺部真菌感染的26例病例进行临床分析。结果:1非霍奇金淋巴瘤合并侵袭性肺真菌感染与霍奇金淋巴瘤合并侵袭性肺真菌感染的诊断率为分别1.6%和3.3%,且年龄与性别之间发生率差异没有显著性,而淋巴瘤化疗后合并造血干细胞移植患者的侵袭性肺真菌感染率大大增加。2真菌感染菌谱分布仍以白色念珠菌为主。326例患者中确诊5例,临床诊断IPFI 12例,拟诊9例。确诊率升高,拟诊率降低。4伊曲康唑、脂质体两性霉素B、伏立康唑及卡泊芬净真菌感染的有效率均超过50%,以伏立康唑疗效最好,有效率73%。结论:白色念珠菌是淋巴瘤化疗后侵袭性肺部真菌感染的主要病原菌,伏立康唑对其具有显著的治疗作用。
Objective：The present study mainly discusses and analyzes the clinical characteristics of invasive pulmonary fungal infections（IPFI）in patients with lymphoma who receiving chemotherapy.Methods：We analyzed 26 patients with lymphoma combining IPFI after receiving chemotherapy.Results：（1）The rate of diagnosis of IPFI in patients with the non-Hodgkin′s lymphoma and Hodgkin′s disease was 1.6%and 3.3%,respectively,in the five years.There was no significantly difference among ages and sexes.IPFI-attributable mortality rate was higher in HSCT patients than those in receiving chemotherapy alone.（2）The infection of Candida albicans was also the majority of the fungus infection.（3）The rate of diagnosis arises,with the suspected rate of diagnosis decreasing.（4）Among the four kinds of antifungal drugs,the curative effect of Voriconazole was the best.Conclusion：Candida albicans is lymphoma after chemotherapy for invasive pulmonary fungal infection of the main pathogenic bacteria of voriconazole in the treatment of its significant effect.
出处
《陕西医学杂志》
CAS
2015年第3期311-312,共2页
Shaanxi Medical Journal
基金
广东省卫生厅科技计划项目(A2011532)
关键词
淋巴瘤
肺病
药物相关副作用及不良反应
细菌感染和真菌病
白色念珠菌
Lymphoma Lung diseases Drug-related side effects and adverse reactions Bacterial intections and mycoses Candida albicans
